|
|
|
|
After the first attack,response rates were 77%for rizatriptan and 37%for placebo(p<0.001).Similar efficacy of rizatriptan,ranging from a 75 to 80% response,was observed in each of the subsequent attacks with no evidence of tolerance to therapeutic effects.Most patients(93%)responded to rizatriptan 10 mg during the first or second attack.Adverse experiences were generally mild and transient,the most common being dizziness and somnolence.Incidents of adverse experiences per attack decreased after the first attack.Rizatriptan 10 mg PO is efficacious and generally well tolerated in acute migraine.Its efficacy is maintained throughout the treatment of multiple,discrete migraine attacks. |
|